Life Sciences view: headlines mask reality within health care

13/07/2017

Download

With revisions to the path of US health care reform expected imminently, Andy Acker and Ethan Lovell, portfolio managers within the Janus Henderson Global Life Sciences Team, outline why they believe opportunities remain within the US health care sector.
 
In the US, the Republican promise to repeal and replace the Affordable Care Act (ACA) has loomed over the health care sector for months. But members of Congress – having recently returned to Washington after the Fourth of July recess – are still trying to fulfil that goal. A Senate bill introduced in late June, the Better Care Reconciliation Act (BCRA), did not have the necessary votes to pass. Senate Majority Leader Mitch McConnell plans to unveil a revised draft imminently. If reform fails, though, he says the Grand Old Party (GOP; the Republican Party) may have to revert to plan B: working with Democrats to stabilise the insurance markets.
 
The downside risk
 
In other words, uncertainty continues. According to the Congressional Budget Office (CBO), in the US 22 million fewer people would have insurance by 2026 under BCRA, driven in large part by deep cuts to federal spending on Medicaid and fewer incentives for people to buy coverage. Given such a bleak forecast, we believe the odds of the Senate approving the current bill are less than 50/50.
 
So what does this mean for investing in health care? In our opinion, hospitals face the most downside risk, regardless of whether the Senate bill becomes law. That’s because we see the number of uninsured and underinsured in the US rising over the near-to-intermediate term. Although the CBO’s forecast may be inflated (the non-partisan group used outdated assumptions to make its projections), if the BCRA becomes law, fewer people would be incentivised to buy coverage (since penalties for not having insurance would be eliminated) and Medicaid benefits would become thinner, hurting hospital revenues. If BCRA does not pass, hospitals could ‘feel the pain’ anyway since a Republican-controlled government could, for instance, decide to inadequately fund ACA subsidies, or more insurers could opt to pull out of money-losing exchanges.
 
Chart 1: US uninsured rate rises
Uncertainty about health care reform could be driving a recent uptick in the rate of uninsurance in the US
 
Source: Gallup-Sharecare Well-Being Index, quarterly data from Q4 2013 to Q2 2017
 
Opportunity despite uncertainty
 
Still, we would point out that hospitals make up only a small portion of the sector, and while reform dominates headlines, many other areas of health care continue to thrive. We are especially encouraged by innovations occurring in biotechnology and medical devices. Today, more companies are developing products that target high, unmet medical needs. At the same time, the US Food and Drug Administration (FDA) is increasingly focused on delivering these therapies quickly to patients. New rules, for example, now allow the FDA and drug sponsors to communicate during the clinical review process, making it possible for sponsors to address deficiencies long before an FDA approval decision is made. As such, the number of product launches is on the rise. In fact, for the five years through 2016, the FDA approved an average of 35 novel therapies annually. During the previous five years, the average was only 24 annually.
 
Chart 2: new drug approvals
The US FDA has been approving novel therapies at a higher rate in recent years
 
Source: US FDA. Data as of 11 July 2017
 
Free-market solutions
 
Drug pricing has been another challenge for the sector ever since Hillary Clinton first tweeted about “price gouging” in 2015. Yet, here again, we believe the headlines mask reality. In our opinion, Republicans are more likely to embrace free-market solutions to contain drug costs in the US, without stifling innovation. Neither the BCRA, nor the health care bill that passed the US House of Representatives earlier this year, address drug costs. A recent draft of an executive order from President Trump even suggested easing some regulations for pharmaceutical companies. Other solutions that have been floated include speeding competition to the market (making it easier to substitute generics* and biosimilars** for brand-name drugs), allowing greater flexibility in benefits design (thereby increasing affordability) and reforming public programmes such as 340B, which gives providers that serve low-income communities deep discounts on drugs – a programme that critics argue is being used to pad profits.
 
We believe these kinds of changes would be beneficial for the system and encourage companies to exercise practices that lead to sustainable growth. For example, before launch, Regeneron Pharmaceuticals and Sanofi met with payers to determine an appropriate price for Dupixent, which addresses moderate-to-severe forms of atopic dermatitis (eczema). The treatment still carries an annual price tag of US$37,000, but prescription trends have been robust. We think these kinds of practices will become increasingly common, benefiting patients and, potentially, investors.
 
 
Please note: Stock examples are intended for illustrative purposes only and are not indicative of the historical or future performance of the strategy or the chances of success of any particular strategy. References made to individual securities should not constitute or form part of any offer or solicitation to issue, sell, subscribe or purchase the security. 
 
Glossary:
*Generic = a generic drug is the same as a brand-name drug in dosage, safety, strength, quality, the way it works, the way it is taken and the way it should be used. FDA requires generic drugs have the same high quality, strength, purity and stability as brand-name drugs.
**Biosimilar = a biosimilar is a biologic medical product which is almost an identical copy of an original product that is manufactured by a different company.

These are the views of the author at the time of publication and may differ from the views of other individuals/teams at Janus Henderson Investors. Any securities, funds, sectors and indices mentioned within this article do not constitute or form part of any offer or solicitation to buy or sell them.

Past performance is not a guide to future performance. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.

The information in this article does not qualify as an investment recommendation.

For promotional purposes.


Important information

Please read the following important information regarding funds related to this article.

Janus Henderson Global Life Sciences Fund

For institutional/ sophisticated investors / accredited investors qualified distributors use only.

All content in this document is for information or general use only and is not specific to any individual client requirements. The information contained in this document is referential and may not be construed as an offer, invitation or recommendation or investment advice, nor should be taken as a basis to take (or stop taking) any decision.

Janus Henderson Capital Funds Plc is a UCITS established under Irish law, with segregated liability between funds. Investors are warned that they should only make their investments based on the most recent Prospectus which contains information about fees, expenses and risks, which is available from all distributors and paying agents, it should be read carefully. An investment in the fund may not be suitable for all investors and is not available to all investors in all jurisdictions; it is not available to US persons.  Past performance is not indicative of future results. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements.  Shares, if redeemed, may be worth more or less than their original cost.

Janus Henderson Group plc and its subsidiaries are not responsible for any unlawful distribution of this document to any third parties, in whole or in part, or for information reconstructed from this document and do not guarantee that the information supplied is accurate, complete, or timely, or make any warranties with regards to the results obtained from its use. As with all investments, there are inherent risks that each individual should address.

The distribution of this document or the information contained in it may be restricted by law and may not be used in any jurisdiction or any circumstances in which its use would be unlawful.

Issued in Europe by Janus Capital International Limited (“JCIL”), authorised and regulated by the U.K. Financial Conduct Authority. Janus Capital International Limited (“JCIL”) is an entity registered and operating under the laws of the United Kingdom and Janus Capital Funds plc. is registered under the legislation of Ireland.

The extract prospectus (edition for Switzerland), the articles of incorporation, the extract annual and semi-annual report, in German, can be obtained free of charge from the representative in Switzerland: First Independent Fund Services Ltd (“FIFS”), Klausstrasse 33, CH-8008 Zurich, Switzerland, tel: +41 44 206 16 40, fax: +41 44 206 16 41, web: http://www.fifs.ch. The Swiss paying agent is: Banque Cantonale de Genève, 17, quai de l’Ile, CH-1204 Geneva. The last share prices can be found on www.fundinfo.com. For Qualified investors, institutional, wholesale client use only. Outside of Switzerland, this document is for professional use only. Not for onward distribution.

This material is strictly private and confidential and may not be reproduced or used for any purpose other than evaluation of a potential investment in Janus Capital International Limited’s products or the procurement of its services by the recipient of this presentation or provided to any person or entity other than the recipient of this presentation.

We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes.

Janus Capital Management LLC serves as investment adviser. Janus, Intech and Perkins are registered trademarks of Janus International Holding LLC. © Janus International Holding LLC. For more information or to locate your country’s Janus representative contact information, please visit www.janushenderson.com.

Specific risks

  • This fund is designed to be used only as one component of several in a diversified investment portfolio. Investors should consider carefully the proportion of their portfolio invested into this fund.
  • If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
  • The Fund may use derivatives with the aim of reducing risk or managing the portfolio more efficiently. However this introduces other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
  • Shares can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
  • If the Fund holds assets in currencies other than the base currency of the Fund or you invest in a share class of a different currency to the Fund (unless 'hedged'), the value of your investment may be impacted by changes in exchange rates.
  • The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
  • Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.

Risk rating

Share

Important message